Abstract Background Glucose-6-phosphate dehydrogenase (G6PD) is cytosolic enzyme,
which has a vital role for the integrity and functioning of red blood cells. Lower activity of this …

Tens of millions of patients diagnosed with vivax malaria cannot safely receive primaquine
therapy against repeated attacks caused by activation of dormant liver stages called …

Abstract Background Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most
prevalent inborn disorder. This X-chromosome-linked recessive disease affects more than …

Primaquine is the only available antimalarial drug that kills dormant liver stages of
Plasmodium vivax and Plasmodium ovale malarias and therefore prevents their relapse …

Background Glucose 6-phosphate dehydrogenase deficiency (G6PDd) plays a central role
in readiness assessment for malaria elimination in Myanmar by 2030 that includes …

Radical cure of Plasmodium vivax malaria in glucose-6-phosphate dehydrogenase (G6PD)
deficient individuals employs weekly primaquine dosing. This is the only recommended …

Accurate measurement of glucose-6-phosphate dehydrogenase (G6PD) activity is critical for
malaria treatment as misclassification of G6PD deficiency could cause serious harm to …

Background The WHO recommends routine testing of G6PD activity to guide radical cure in
patients with Plasmodium vivax malaria. Females may have intermediate G6PD enzyme …

Background Primaquine is an approved radical cure treatment for Plasmodium vivax malaria
but treatment can result in life-threatening hemolysis if given to a glucose-6-phosphate …

Abstract Background Glucose-6-phosphate dehydrogenase (G6PD; EC 1.1. 1.49) deficiency
is one of the most common X-linked recessive hereditary disorders in the world. Primaquine …